Baseline Characteristics of Patients With Kaposi’s Sarcoma–Associated Herpesvirus Inflammatory Cytokine Syndrome (n = 6) and All Other Group 4 Patients (n = 153)
| Characteristic . | Possible KICS Subjects (n = 6) . | Remainder of Patients Without Microbiologically Proven Coinfection (n = 153) . | P Value . |
|---|---|---|---|
| Confirmed death | 5 (83.3) | 28 (18.3) | .002 |
| Male sex | 4 (67) | 61 (39.9) | .227 |
| Age, y, median (range) | 47 (26–74) | 38 (19–81) | .049 |
| Weight, kg, median (range) | 58 (35–71) | 53.0 (30–99) | .912 |
| Receiving ART | 3 (50) | 63 (41.2) | .290 |
| HIV-VL, copies/mL, median (range) | 81 298 (29–3 507 840) | 70 363 (29–7 934 692) | .978 |
| CD4 count, cells/μL, median (range) | 106.5 (10–328) | 97 (2–519) | .818 |
| KSHV seropositive | 6 (100) | 55 (35.9) | .003 |
| Skin KS | 1 (16.7) | 4 (2.6) | .177 |
| Characteristic . | Possible KICS Subjects (n = 6) . | Remainder of Patients Without Microbiologically Proven Coinfection (n = 153) . | P Value . |
|---|---|---|---|
| Confirmed death | 5 (83.3) | 28 (18.3) | .002 |
| Male sex | 4 (67) | 61 (39.9) | .227 |
| Age, y, median (range) | 47 (26–74) | 38 (19–81) | .049 |
| Weight, kg, median (range) | 58 (35–71) | 53.0 (30–99) | .912 |
| Receiving ART | 3 (50) | 63 (41.2) | .290 |
| HIV-VL, copies/mL, median (range) | 81 298 (29–3 507 840) | 70 363 (29–7 934 692) | .978 |
| CD4 count, cells/μL, median (range) | 106.5 (10–328) | 97 (2–519) | .818 |
| KSHV seropositive | 6 (100) | 55 (35.9) | .003 |
| Skin KS | 1 (16.7) | 4 (2.6) | .177 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; KICS, Kaposi’s sarcoma–associated herpesvirus inflammatory cytokine syndrome; KS, Kaposi’s sarcoma; KSHV, Kaposi’s sarcoma–associated herpesvirus; VL, viral load.
Baseline Characteristics of Patients With Kaposi’s Sarcoma–Associated Herpesvirus Inflammatory Cytokine Syndrome (n = 6) and All Other Group 4 Patients (n = 153)
| Characteristic . | Possible KICS Subjects (n = 6) . | Remainder of Patients Without Microbiologically Proven Coinfection (n = 153) . | P Value . |
|---|---|---|---|
| Confirmed death | 5 (83.3) | 28 (18.3) | .002 |
| Male sex | 4 (67) | 61 (39.9) | .227 |
| Age, y, median (range) | 47 (26–74) | 38 (19–81) | .049 |
| Weight, kg, median (range) | 58 (35–71) | 53.0 (30–99) | .912 |
| Receiving ART | 3 (50) | 63 (41.2) | .290 |
| HIV-VL, copies/mL, median (range) | 81 298 (29–3 507 840) | 70 363 (29–7 934 692) | .978 |
| CD4 count, cells/μL, median (range) | 106.5 (10–328) | 97 (2–519) | .818 |
| KSHV seropositive | 6 (100) | 55 (35.9) | .003 |
| Skin KS | 1 (16.7) | 4 (2.6) | .177 |
| Characteristic . | Possible KICS Subjects (n = 6) . | Remainder of Patients Without Microbiologically Proven Coinfection (n = 153) . | P Value . |
|---|---|---|---|
| Confirmed death | 5 (83.3) | 28 (18.3) | .002 |
| Male sex | 4 (67) | 61 (39.9) | .227 |
| Age, y, median (range) | 47 (26–74) | 38 (19–81) | .049 |
| Weight, kg, median (range) | 58 (35–71) | 53.0 (30–99) | .912 |
| Receiving ART | 3 (50) | 63 (41.2) | .290 |
| HIV-VL, copies/mL, median (range) | 81 298 (29–3 507 840) | 70 363 (29–7 934 692) | .978 |
| CD4 count, cells/μL, median (range) | 106.5 (10–328) | 97 (2–519) | .818 |
| KSHV seropositive | 6 (100) | 55 (35.9) | .003 |
| Skin KS | 1 (16.7) | 4 (2.6) | .177 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; KICS, Kaposi’s sarcoma–associated herpesvirus inflammatory cytokine syndrome; KS, Kaposi’s sarcoma; KSHV, Kaposi’s sarcoma–associated herpesvirus; VL, viral load.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
